INTRODUCTION AND OBJECTIVES: Interleukin 10 (IL-10) is an anti-inflammatory cytokine that inhibits the synthesis of proinflammatory cytokines. It has been shown that IL-10 is released into the circulation during post-ischemic myocardial reperfusion. The objective of this study was to determine whether the serum IL-10 concentration in patients with acute myocardial infarction who were undergoing primary angioplasty was related to the subsequent presence or absence of heart failure. PATIENTS AND METHOD: The study included 65 patients who underwent successful primary angioplasty. During their subsequent stay in the coronary unit, their maximum degree of heart failure was recorded. Patients were then divided into 2 groups: group A patients were in Killip class I and group B patients in Killip classes II-IV. The serum IL-10 concentration was measured during the 24 hours following admission to the coronary unit. RESULTS: The 2 groups were similar with regard to age, sex, and coronary risk factors. The IL-10 concentration was significantly higher in the group of patients with acute myocardial infarction without heart failure than in the group with heart failure (30.4+/-10.8 vs 19.8+/-7.9 pg/mL; P<.001). CONCLUSIONS: In patients with acute myocardial infarction who had undergone successful primary angioplasty, the serum IL-10 concentration measured during the following 24 hours was significantly higher in those who did not develop heart failure. These findings suggest that this anti-inflammatory cytokine has a protective effect on the myocardium during ischemia or reperfusion, or both.
RCT Entities:
INTRODUCTION AND OBJECTIVES:Interleukin 10 (IL-10) is an anti-inflammatory cytokine that inhibits the synthesis of proinflammatory cytokines. It has been shown that IL-10 is released into the circulation during post-ischemic myocardial reperfusion. The objective of this study was to determine whether the serum IL-10 concentration in patients with acute myocardial infarction who were undergoing primary angioplasty was related to the subsequent presence or absence of heart failure. PATIENTS AND METHOD: The study included 65 patients who underwent successful primary angioplasty. During their subsequent stay in the coronary unit, their maximum degree of heart failure was recorded. Patients were then divided into 2 groups: group A patients were in Killip class I and group B patients in Killip classes II-IV. The serum IL-10 concentration was measured during the 24 hours following admission to the coronary unit. RESULTS: The 2 groups were similar with regard to age, sex, and coronary risk factors. The IL-10 concentration was significantly higher in the group of patients with acute myocardial infarction without heart failure than in the group with heart failure (30.4+/-10.8 vs 19.8+/-7.9 pg/mL; P<.001). CONCLUSIONS: In patients with acute myocardial infarction who had undergone successful primary angioplasty, the serum IL-10 concentration measured during the following 24 hours was significantly higher in those who did not develop heart failure. These findings suggest that this anti-inflammatory cytokine has a protective effect on the myocardium during ischemia or reperfusion, or both.
Authors: Mira Jung; Yonggang Ma; Rugmani Padmanabhan Iyer; Kristine Y DeLeon-Pennell; Andriy Yabluchanskiy; Michael R Garrett; Merry L Lindsey Journal: Basic Res Cardiol Date: 2017-04-24 Impact factor: 17.165
Authors: Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; Lilian Grigorian-Shamagian; José M García-Acuña; Pablo Aguiar-Souto; Michel Jacquet-Hervet; María V Reino-Maceiras; Ezequiel Alvarez; José R González-Juanatey Journal: Cardiovasc Diabetol Date: 2012-08-21 Impact factor: 9.951
Authors: Martina Kolackova; Jan Krejsek; Vladimir Svitek; Pavel Kunes; Jiri Mandak; Zdenka Holubcova; Vladimir Lonsky Journal: Mediators Inflamm Date: 2012-02-19 Impact factor: 4.711
Authors: Nicholas Stafford; Farryah Assrafally; Sukhpal Prehar; Min Zi; Ana M De Morais; Arfa Maqsood; Elizabeth J Cartwright; Werner Mueller; Delvac Oceandy Journal: Front Pharmacol Date: 2020-10-30 Impact factor: 5.810